This study aims to evaluate the EUS-RFA in terms of efficacy for pain management and improvement in quality-of-life parameters for patients with advanced inoperable pancreatic cancer. The primary objectives of this study are to 1) evaluate the utility of EUS-RFA for pain control and improvement in quality-of-life parameters for patients with advanced pancreatic cancer; 2) to measure the reduction of analgesic medications' requirements in patients affected by inoperable pancreatic cancer.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Pain severity-BPI
Timeframe: From Baseline up to 3 Months
Pain severity-VAS
Timeframe: From Baseline up to 3 Months
Pain severity-NRS
Timeframe: From Baseline up to 3 Months
Quality of Life (EORTC PAN26)
Timeframe: From Baseline up to 3 Months
Quality of Life (EORTC C30)
Timeframe: From Baseline up to 3 Months
Quality of Life (NFHSI)
Timeframe: From Baseline up to 3 Months
Concomitant Analgesic/Narcotic Use
Timeframe: From Baseline up to 3 Months